180
Participants
Start Date
August 17, 2025
Primary Completion Date
April 6, 2027
Study Completion Date
April 6, 2027
JS203 in combination with gemcitabine and oxaliplatin
Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
JS203 in combination with ifosfamide, carboplatin and etoposide
Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
JS203 combined with lenalidomide
lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.
RECRUITING
Beijing Cancer Hospital, Beijing
Shanghai Junshi Bioscience Co., Ltd.
OTHER